RE: RNS Monday morning?11 Apr 2022 05:38
the Company's in-house technology and R&D pipeline has identified eight market sectors where we can either manufacture products ourselves or work in partnerships where the partners' IP, manufacturing capability, routes to market or other capabilities can be enhanced using our in-house skills or technology.
In addition to these organic growth initiatives within Pharm2Farm, the Group is actively looking at growing its technology and market presence in the nanotechnology and advanced materials space through complimentary acquisitions.....
Its time for another JV